COVID-19

Pfizer is Buying a Cardiovascular Biopharma Company for $6.7Bn

Arena is a biopharmaceutical company focused in part on cardiovascular and inflammatory medicines to a global patient cohort.

Photo: thenationalpulse.com

What’s your Reaction?

LeftNeutralRight

Now, why would Pfizer buy cardiovascular biopharma company?

Pfizer is about to buy Arena Pharmaceuticals for $6.7 billion. Arena is a biopharmaceutical company focused in part on cardiovascular and inflammatory medicines to a global patient cohort. A majority of mainstream news outlets have focused their reportage on Arena’s bowel disease treatment, while failing to mention the firm’s cardiovascular research.

Read full article here: thenationalpulse.com

What’s your Reaction?

LeftNeutralRight

Click to comment

Leave a Reply

Your email address will not be published.

To Top